EXAS
Exact Sciences Corporation · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 1 | -143 | 11.48K | $1.20M | — | −144 |
| Q4 2025 | 146 | +2 | 107.45M | $10.91B | +5 | −2 |
| Q3 2025 | 23 | +1 | 95.08M | $5.20B | +1 | −1 |
| Q2 2025 | 20 | 0 | 105.61M | $5.61B | — | — |
| Q1 2025 | 17 | -2 | 51.51M | $2.23B | +1 | −3 |
| Q4 2024 | 19 | +2 | 51.81M | $2.91B | +3 | −1 |
| Q3 2024 | 16 | -2 | 41.47M | $2.82B | — | −2 |
| Q2 2024 | 18 | — | 42.26M | $1.79B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 11.48K | -87.7% | $1.20M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| BlackRock | $1.54B | was 0.0% |
| State Street Global Advisors | $424.83M | was 0.0% |
| Balyasny Asset Management L.P. | $415.38M | was 0.8% |
| Millennium Management | $349.52M | was 0.3% |
| Norges Bank | $348.43M | was 0.0% |
| Geode Capital Management | $338.43M | was 0.0% |
| Morgan Stanley | $330.10M | was 0.0% |
| UBS Group AG | $303.60M | was 0.1% |
| Massachusetts Financial… | $276.59M | was 0.1% |
| AQR Capital Management | $226.41M | was 0.1% |
| Qube Research & Technologies… | $204.77M | was 0.3% |
| Tudor Investment Corp Et Al | $200.95M | was 1.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 9 holders, 64.35K shares, $4.50M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.